China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA approves Tregzi for chronic graft-versus-host disease

FDA approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.

July 02, 2026

Vol.52 No.26

Drugs & Targets

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq) for the treatment of patients with stage 3 colon cancer with deficient deoxyribonucleic acid mismatch repair.

June 18, 2026

Vol.52 No.24

Drugs & Targets

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

FDA approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

FDA approved an oral combination of Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

May 15, 2026

Vol.52 No.19

China has outpaced the U.S. in novel cancer drug approvals since 2023, Friends analysis shows

YOU MAY BE INTERESTED IN

FDA approves Trodelvy for first-line treatment of mTNBC

FDA approves Tregzi for chronic graft-versus-host disease

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment

FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Renew today!

Subscriber content

Never miss an issue!

Login